Corneas harvested from patients who died of drowning are viable for transplantation

News
Article

Postoperative outcomes of the tissues obtained from these donors were satisfactory

A doctor reviews paperwork with a woman. Image credit: ©Drazen – stock.adobe.com

Details of the quality of the corneal tissue and the outcomes after the corneal transplantations were collected from the eye bank and outpatient records. Image credit: ©Drazen – stock.adobe.com

Donor corneas obtained from individuals who drowned are safe for transplantation,1 according to researchers from the Cornea and Anterior Segment Service, L V Prasad Eye Institute, Bhubaneswar, Odisha, India.

Kshyanaprava Priyadarshini, MS, first author of the study, described the retrospective investigation that led to this result. The aim of this study, she recounted, was to analyse the tissue quality and outcomes of corneal transplantations from donor corneal tissues harvested from drowning victims from March 2018 to September 2022. The details of the quality of the corneal tissue and the outcomes after the corneal transplantations were collected from the eye bank and outpatient records.

Over the course of the study, 34 donor corneas were obtained from drowning victims who were a mean age of 37.1 ± 20.3 years. The mean time from when the tissue was obtained to its preservation was 4.9 ± 2.6 hours.

The mean endothelial cell density of the donor corneas was 3,025 ± 271 cells/mm2. Of the 34 corneas, 20 (58.8%) were transplanted at the L V Prasad Eye Institute, 2 were stored in glycerol for future use, and 12 were transported to other transplantation centers. Overall, 94.1% or 32 corneas were transplanted.

Of the 20 corneas used at the L V Prasad Eye Institute, 17 were used for optical grafts and 3 for therapeutic indications, according to Ms Priyadarshini. Of the 17 optical grafts, 10 were used for optical penetrating keratoplasty, 6 for endothelial keratoplasty and 1 for anterior lamellar keratoplasty. The most common indication for keratoplasty was regrafting because of a previously failed graft (25%), she reported. No infections developed in any of the transplanted eyes during the immediate postoperative period. Eight eyes had clear grafts after 3 months.

Of the 12 tissues transferred to other keratoplasty centers, 10 were used for optical grafts and 2 for therapeutic/tectonic grafts.

The researchers concluded, “Donor corneas retrieved from drowning victims may be considered safe for transplantation. The postoperative outcomes of the tissues obtained from these donors were satisfactory. Hence, these donor corneas can be optimally used in routine transplantation procedures.”

Reference

1. PriyadarshiniK,Das S, Sahu SK, et al. Safety and efficacy profile of corneas harvested from donors of drowning victims. Cornea. 2024;43:141-145; doi: 10.1097/ICO.0000000000003321

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.